Skip to main content
Top

Extreme thrombocytosis and ANCA-associated vasculitis in an adult patient: a case report

Published in:

Abstract

Introduction

We describe the case of a 39-year-old woman who presented with extreme reactive thrombocytosis as a prominent and unusual feature in the context of anti-neutrophil cytoplasmic antibody (myeloperoxidase, MPO)-associated vasculitis. To our knowledge, this is the first reported case in an adult patient where marked thrombocytosis was part of the initial presentation of ANCA-associated vasculitis.

Case Presentation

The patient presented with a two-month history of constitutional symptoms and polyarticular pain. Laboratory evaluation revealed extreme thrombocytosis, impaired renal function, and positive MPO-ANCA. Renal biopsy demonstrated rapidly progressive pauci-immune crescentic glomerulonephritis consistent with MPA. Based on these findings, a diagnosis of ANCA-associated vasculitis was established. Treatment with high-dose corticosteroids and intravenous cyclophosphamide led to clinical improvement, including resolution of thrombocytosis and recovery of renal function.

Conclusions

Although the clinical features of ANCA-associated vasculitis were typical, the presence of extreme thrombocytosis may indicate a heightened inflammatory response and deserves careful evaluation. Early recognition and prompt treatment are essential to prevent irreversible organ damage and other complications.
Title
Extreme thrombocytosis and ANCA-associated vasculitis in an adult patient: a case report
Authors
Andrés Hormaza-Jaramillo
Maria J. Varela
Daniela Peñaloza Gonzalez
Sara Alejandra Benavides-Ibarra
Carlos Jimenez
David Aguirre-Valencia
Publication date
13-11-2025
Publisher
BioMed Central
Published in
BMC Rheumatology / Issue 1/2025
Electronic ISSN: 2520-1026
DOI
https://doi.org/10.1186/s41927-025-00562-3
This content is only visible if you are logged in and have the appropriate permissions.

Keynote webinar | Spotlight on advances in lupus

Systemic lupus erythematosus is a severe autoimmune disease that can cause damage to almost every system of the body. Learn more about novel biomarkers for diagnosis and monitoring, and familiarize yourself with current and emerging targeted therapies.

Prof. Edward Vital
Prof. Ronald F. van Vollenhoven
Watch now
Video

Elevate your expertise in aplastic anemia (Link opens in a new window)

Transform the way you care for your patients with aplastic anemia with our 3-module series using real-world case studies and expert insights. Discover why early diagnosis matters, explore the benefits and risks of current treatments, and develop tailored approaches for complex cases. 

Supported by:
  • Pfizer
Developed by: Springer Health+ IME
Learn more
Image Credits
Renal biopsy of patient with thrombocytosis and ANCA-associated vasculitis/© 2025, Andrés Hormaza-Jaramillo et al, BMC Rheumatol, Lupus concept/© (M) Vitalii But / stock.adobe.com / Generated with AI, Aplastic Anemia/© Springer Healthcare IME